Verona Pharma Statistics
Total Valuation
Verona Pharma has a market cap or net worth of $9.11 billion. The enterprise value is $8.92 billion.
Important Dates
The last earnings date was Wednesday, August 6, 2025, before market open.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Verona Pharma has 86.19 million shares outstanding. The number of shares has increased by 4.10% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 86.19M |
| Shares Change (YoY) | +4.10% |
| Shares Change (QoQ) | +7.04% |
| Owned by Insiders (%) | 4.35% |
| Owned by Institutions (%) | 84.46% |
| Float | 70.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 65.70 |
| PS Ratio | 39.90 |
| Forward PS | 15.97 |
| PB Ratio | 32.64 |
| P/TBV Ratio | 32.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 40.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.71, with a Debt / Equity ratio of 0.88.
| Current Ratio | 10.71 |
| Quick Ratio | 10.25 |
| Debt / Equity | 0.88 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.45 |
Financial Efficiency
Return on equity (ROE) is -36.36% and return on invested capital (ROIC) is -8.28%.
| Return on Equity (ROE) | -36.36% |
| Return on Assets (ROA) | -6.68% |
| Return on Invested Capital (ROIC) | -8.28% |
| Return on Capital Employed (ROCE) | -10.32% |
| Revenue Per Employee | $1.06M |
| Profits Per Employee | -$388,455 |
| Employee Count | 209 |
| Asset Turnover | 0.44 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Verona Pharma has paid $8.24 million in taxes.
| Income Tax | 8.24M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +293.16% in the last 52 weeks. The beta is 0.12, so Verona Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.12 |
| 52-Week Price Change | +293.16% |
| 50-Day Moving Average | 101.50 |
| 200-Day Moving Average | 69.22 |
| Relative Strength Index (RSI) | 67.48 |
| Average Volume (20 Days) | 1,589,811 |
Short Selling Information
| Short Interest | 2.47M |
| Short Previous Month | 4.06M |
| Short % of Shares Out | 2.99% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.35 |
Income Statement
In the last 12 months, Verona Pharma had revenue of $221.67 million and -$81.19 million in losses. Loss per share was -$1.03.
| Revenue | 221.67M |
| Gross Profit | 210.93M |
| Operating Income | -53.85M |
| Pretax Income | -123.69M |
| Net Income | -81.19M |
| EBITDA | -52.74M |
| EBIT | -53.85M |
| Loss Per Share | -$1.03 |
Full Income StatementBalance Sheet
The company has $438.02 million in cash and $244.37 million in debt, giving a net cash position of $193.64 million or $2.25 per share.
| Cash & Cash Equivalents | 438.02M |
| Total Debt | 244.37M |
| Net Cash | 193.64M |
| Net Cash Per Share | $2.25 |
| Equity (Book Value) | 278.27M |
| Book Value Per Share | 3.24 |
| Working Capital | 497.61M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$72.49 million and capital expenditures -$1.07 million, giving a free cash flow of -$73.56 million.
| Operating Cash Flow | -72.49M |
| Capital Expenditures | -1.07M |
| Free Cash Flow | -73.56M |
| FCF Per Share | -$0.85 |
Full Cash Flow StatementMargins
Gross margin is 95.15%, with operating and profit margins of -24.29% and -36.62%.
| Gross Margin | 95.15% |
| Operating Margin | -24.29% |
| Pretax Margin | -32.91% |
| Profit Margin | -36.62% |
| EBITDA Margin | -23.79% |
| EBIT Margin | -24.29% |
| FCF Margin | n/a |
Dividends & Yields
Verona Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.10% |
| Shareholder Yield | -4.10% |
| Earnings Yield | -0.89% |
| FCF Yield | -0.81% |
Dividend DetailsAnalyst Forecast
The average price target for Verona Pharma is $114.10, which is 7.97% higher than the current price. The consensus rating is "Buy".
| Price Target | $114.10 |
| Price Target Difference | 7.97% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 119.29% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Verona Pharma has an Altman Z-Score of 7.99 and a Piotroski F-Score of 2.
| Altman Z-Score | 7.99 |
| Piotroski F-Score | 2 |
